Polyoxometalates are clusters of inorganic molecules which principally comprise oxide anions and early transition-metal cations. The polyoxometalates have been shown to exhibit activity in vitro and in vivo against a number of RNA and DNA viruses (1, 9, 18). We recently reported on the antimyxovirus activity of K 10 Fe 4 (H 2 O) 2 (PW 9 O 34 ) 2 n ⅐ H 2 O (HS-058). HS-058 was shown to inhibit the adsorption of respiratory syncytial virus (RSV) to the cell membrane and to do so at a later step than adsorption in the course of influenza virus (FluV) replication (16). (PriNH 3 ) 6 H[PTi 2 W 10 O 38 (O 2 ) 2 ] ⅐ H 2 O (where Pri is isopropanol), a Keggin-type polyoxometalate (PM-523) was shown to inhibit the replication of influenza virus (FluV) A, FluV B, RSV, measles virus, and parainfluenza virus type 2 in vitro. PM-523 was toxic to Mardin-Darby canine kidney (MDCK) cells, HEp-2 cells, and HMV-2 cells to only a very slight degree, and the median cytotoxic concentration (CC 50 ) was found to be comparable to that of ribavirin (17). Elucidation of the mechanism of the antiviral action of PM-523 has revealed its inhibitory activity on the fusion of the viral envelope and the cell membrane, which is the first step in the entry of FluV into cells (17). This is quite different from the antiviral action of ribavirin, which inhibits viral RNA synthesis through inhibition of the activities of the multiple enzymes involved in viral RNA synthesis (2, 8) . In this study we tested combinations of PM-523 and ribavirin for their effects on FluV A replication. We found that these compounds synergistically inhibit FluV A replication in both in vitro and in vivo infection models of FluV.
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MATERIALS AND METHODS
Virus, cells, and animals. FluV A strain FluV/A/PR8/34/H1N1 was used throughout the experiments. The virus was passaged more than 10 times in embryonated chicken eggs and three times in MDCK cells in the presence of 2 g of trypsin per ml in the laboratory at Fukushima Medical College. Stock virus had a titer of 10 8 /ml as the 50% tissue culture infective dose (TCID 50 ) and was stored at Ϫ80°C until use. MDCK cells were used for virus titration and antiviral assay of the compounds in vitro. Cells were grown in Eagle's minimal essential medium supplemented with 100 g of streptomycin per ml, 100 U of penicillin G per ml, and 10% newborn calf serum. When cells were infected with virus, the growth medium was changed to a maintenance medium in which newborn calf serum was substituted with 2% heat-inactivated fetal calf serum and 2 g of trypsin per ml. The viral infectivity was determined by using a 2-day culture of MDCK cells. Tenfold serial dilutions of virus in the maintenance medium were inoculated into the cell culture, which was further incubated at 35°C for 7 days. At 7 days after infection a typical cytopathic effect of FluV was observed and the TCID 50 was determined by the method of Reed and Muench (15) (21) . This compound has been fully characterized by chemical analysis and nuclear magnetic resonance and infrared spectroscopies (21) . Ribavirin was provided by Yamasa Corp. (Choshi, Japan). Stock solutions of these compounds were freshly prepared in maintenance medium at a concentration of 3.2 mM for in vitro experiments. Antiviral assay. Evaluation of anti-FluV activity was based on the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (14, 17) . Briefly, a serial twofold dilution of compound starting at 200 M (100-l aliquots in maintenance medium) was prepared in a 96-well tissue culture tray (Falcon TC plate 3077; Becton Dickinson Co., Lincoln Park, N.J.), with three wells used for each concentration. To each well, 10 4 cells (in 50 l of maintenance medium) and virus with infectivity of 100 TCID 50 s (in 50 l of maintenance medium) were added. The tray was centrifuged at 700 ϫ g for 5 min and was incubated at 35°C for 5 days. During the incubation, at 3 days after infection, maintenance medium in each well was exchanged for fresh medium which contained the same concentration of compound as before the exchange. To determine the median effective concentrations (EC 50 s) or the 70% effective concentrations (EC 70 ) of the compounds, 20 l of MTT at a concentration of 7 g/ml in phosphate-buffered saline (pH 7.2) was added to each well. The mixture was incubated at 37°C for 2 h, and reduced MTT (formazan) was extracted from the cells by the addition of 100 l of acidic isopropanol containing 4% Triton X-100. The absorbance of the formazan was measured by using a computercontrolled microplate reader (model 3550; Bio-Rad Hercules, Calif.) at two different wavelengths (540 and 690 nm). Thus, the viabilities of mock-infected and infected cells were evaluated by using the absorbance values of formazan. The EC 50 of a compound was defined as the concentration that achieved 50% protection of virus-infected cells from virus-induced destruction. The percent protection was calculated by using the following formula:
, where (OD T )V, (OD C )V, and (OD C )M indicate the absorbance (optical density [OD] ) of the test sample, the virus-infected control (no compound), and the mock-infected control (no virus and no compound), respectively.
Cytotoxicity. The cytotoxicities of the compounds against MDCK cells were evaluated in terms of the CC 50 . Two-day cultures of MDCK cells were exposed to several concentrations of compound in maintenance medium without trypsin at 35°C for 6 days. The viabilities of the cells were assessed by the MTT method and the trypan blue (TB) exclusion method.
Evaluation of effects of the combination. For each combination of diluted PM-523 and ribavirin, 3 wells of a 96-well tissue culture tray containing MDCK cells in each well were used in the in vitro test. Twofold serial dilutions from 0.8 mM stock solutions of PM-523 and ribavirin were combined as a checkerboard cross. The effect of the combination of PM-523 and ribavirin on FluV replication in vitro was evaluated by using the median-effect principle and the isobologram method and was analyzed by using a microcomputer dose-effect analysis software program (6, 7). The experiment was repeated three times, and the percent inhibition of virus replication was calculated from the average data for the three experiments. Predicted percent inhibition values were derived from a theoretical dose-response curve generated from individual dose-response data for PM-523 and ribavirin, assuming that the effects of the two drugs on viral replication are additive. The degree of interaction of the two compounds was determined by calculating the combination index (CI):
In this equation d1 and d2 indicate the fractional doses of combinations of compounds 1 and 2, respectively, which are required for a median effect or 70% inhibitory effect (e.g., the affected fraction is 50 or 70% that of the control). D1 and D2 are the doses of compounds 1 and 2, respectively, which are required to produce the same median effect or 70% inhibitory effect when these compounds are used singly. ␣ is 0 for mutually exclusive drugs, and ␣ is 1 for mutually nonexclusive drugs. CIs of Ͻ1, 1, and Ͼ1 indicate synergism, summation, and antagonism, respectively (4, 6, 7) .
Experimental infection and treatment of mice. Inbred female BALB/c mice were purchased from Funabashi Nojo Co. and were kept in a pathogen-free environment before the start of the experiments. Eight-week-old mice were infected intranasally with 10 lethal doses of FluV/A/PR8 (titer, 1.6 ϫ 10 4 TCID 50 s; titers were determined with MDCK cells) per mouse. From 8 h after infection, mice were treated with aerosols of PM-523 and ribavirin either singly or in combination every 12 h for 4 days. Compound solutions were prepared in phosphate-buffered saline (pH 7.2), and infected mice were exposed to these compounds by using a continuous aerosol generator (Shibata Scientific Technology, Sendai, Japan) for 2 h at a rate of distribution of 120 l of solution per h to each chamber. One infected mouse was placed in a chamber separately. The average diameter of the aerosol particles was set to be 2.1 m. In this experiment, the dose of the compound given to the mice was expressed in terms of the concentration of compound in the stock solution used for the aerosol exposure. If we treat a 20-g mouse with 40 mM ribavirin (10 mg/ml) or 2.4 mM PM-523 (10 mg/ml) by aerosol exposure, the mouse will be exposed to 0.24 mg of compound/ g/day. The infected mice were observed for the onset of disease (evidenced by fever, trembling, and weak respiration) and death for a period of 2 weeks. Ten infected mice were used for each treatment and control regimen. EC 50 s were determined and were the concentrations of compound in stock solution which achieved 50% protection of infected mice from death on the 9th day after infection.
Titration of infectious virus in mouse lung. Mice were infected and treated in the same manner as described above. The lungs of three infected mice in each group which had been treated with PM-523 and ribavirin singly or in combination were removed at 24-h intervals from 24 to 96 h after infection. The lungs were observed for color and consolidation and were weighed. Then they were homogenized (Hitachi 30; Hitachi Koki Co., Hitachi, Japan), diluted with the same volume of maintenance medium, and centrifuged at 700 ϫ g for 10 min. The infectivity of virus in the supernatant was determined from the TCID 50 by using MDCK cell monolayers. Infectivity was expressed as the numbers of TCID 50 s per gram of lung tissue.
Statistical analysis. The statistical significance of the survival rates of infected mice was assessed by the two-tailed Student t test.
RESULTS
In vitro effect of combinations of PM-523 and ribavirin. The anti-FluV activities of PM-523 and ribavirin were investigated with respect to inhibition of replication in MDCK cells by the MTT method. When PM-523 and ribavirin were individually tested for anti-FluV activity, EC 50 s were found to be 30 and 34 M, respectively. For PM-523 and ribavirin in combination at a ratio of 1:16, the EC 50 was 27 M. For PM-523 and ribavirin individually, EC 70 s were 48 and 72 M, respectively, and for a 1:16 combination the EC 70 was 39 M. Thus, lower EC 50 s and EC 70 s were obtained for the 1:16 combination than for PM-523 and ribavirin individually. For combinations of PM-523 and ribavirin at ratios of 1:128 to 1:1, the observed percent inhibition exceeded the predicted percent inhibition of virus replication (estimated from the additive effect of the two compounds) which means that a synergistic antiviral effect was observed (Table 1 ; Fig. 1 ). The degree of synergism was greater than 23% for combinations of 3.12 M PM-523 and 50 or 100 M ribavirin.
The effectiveness of the drug combination was examined by using isobolograms at endpoints of the EC 50 and the EC 70 , and the fractional inhibitory concentration (FIC) was calculated. FICs were lower than 1.0 for the combination of PM-523 and ribavirin at ratios of 1:4, 1:16, and 1:64 (data not shown). When the CI was calculated, CIs consistently lower than 1.0 were obtained at several endpoints of inhibition (Fig. 2) .
Cytotoxicity of PM-523 and ribavirin in combination. The viabilities of MDCK cells at 6 days after the continuous exposure of cells to compounds were determined. The CC 50 s of PM-523 and ribavirin calculated by the MTT and TB exclusion methods were more than 400 M except for that of ribavirin when the TB exclusion method was used. Combinations of PM-523 and ribavirin did not exhibit increased cytotoxicity compared with the toxicities of the compounds used individually, as determined by the TB exclusion method. As determined by the MTT method, however, the combination of 400 M (each) PM-523 and ribavirin exhibited a slightly increased cytotoxicity compared with the cytotoxicities of the compounds used individually at 400 M. Fifty percent inhibition of cell viability was not obtained at the maximum concentrations of PM-523 and ribavirin in combination (400 plus 400 M) (Table 2).
Antiviral activities of PM-523 and ribavirin used singly and in combination to treat FluV A-infected mice. One hundred percent of the control mice which were infected with FluV A and not treated with the compounds died on the 9th day following infection. Similarly, all mice which were treated with 2.4 mM PM-523, 40 mM ribavirin, and a combination of 1.2 mM PM-523 and 20 mM ribavirin died on the 10th day following infection (Fig. 3) . Half of the mice which were treated with 4.8 mM PM-523 survived to the 9th day following infection. In the groups treated with 240 or 80 mM ribavirin, 80 and 60% of the mice survived, respectively. The EC 50 s of PM-523 and ribavirin on the 9th day of infection were calculated and were 4.8 and 70 mM, respectively (Fig. 3) . When 2.4 mM PM-523 (0.5 the EC 50 on the 9th day) and 40 mM ribavirin (0.57 the EC 50 ) were combined and used to treat the infected mice, 80% of the mice survived to the 9th day following infection. At the end of the experiment (14 days after infection, as indicated in Fig. 3) , survival was found for 60, 40, 30, and 20% of the infected mice in the groups in which a combination of 2.4 mM PM-523 and 40 mM ribavirin, 240 mM ribavirin alone, 80 mM ribavirin alone, and 4.8 mM PM-523 alone were used, respectively. Thus, the survival rates for mice treated with a combination of PM-523 and ribavirin at a ratio of 1:16 were significantly higher than those for mice in groups which received treatment with either compound singly at the same dose and those for mice in groups which received a single treatment of twice the dose of PM-523 (4.8 mM) and ribavirin (80 mM) used throughout the experiment (Fig. 3) .
Virus titers in lungs of infected mice. The lungs of infected and untreated mice or mice treated with 2.4 mM PM-523 or 40 mM ribavirin alone swelled and became red due to congestion. On the other hand, the lungs of infected mice treated with a combination of 2.4 mM PM-523 and 40 mM ribavirin remained grayish white and were not congested (data not shown). Virus titers in the lungs of infected mice were determined for four groups of mice: untreated mice, mice treated with either 2.4 mM PM-523 or 40 mM of ribavirin alone, and mice treated with a combination of 2.4 mM PM-523 and 40 mM ribavirin. Virus titers in infected mouse lungs increased to 10 5.4 TCID 50 s/g at 48 h following infection and decreased thereafter to 10 tion of PM-523 and ribavirin were consistently lower than those in the lungs of control mice or those treated with the compounds individually (Fig. 4) .
DISCUSSION
Polyoxometalates exhibit activities against a broad spectrum of enveloped viruses such as orthomyxoviruses, paramyxoviruses, herpesviruses, and retroviruses. PM-523, a Keggin-type polyoxotungstate, exhibited activities against FluV-A and FluV-B, RSV, measles virus, and parainfluenza virus type 2 (17) . The mechanism of anti-FluV A action of PM-523 was investigated, and PM-523 was shown to inhibit fusion of the viral envelope and cellular membrane by a fluorescence dequenching method (17) . A combination of ribavirin and PM-523 is expected to exhibit additive or synergistic effects against FluV because the inhibitory actions of the two compounds against virus replication are quite different. As indicated in Fig.  1 and Table 1 , the two compounds worked synergistically against the cytopathic effect of FluV in MDCK cells. Calculated CIs were routinely less than 1 at every point of the fraction affected. Thus, the in vitro synergistic effect of PM-523 and ribavirin prompted us to determine the in vivo therapeutic effect of this combination against FluV infection in mice.
Combination effects of ribavirin and other anti-FluV agents in in vitro experiments have been reported by several workers (11, 12) . Combination effects of ribavirin and either rimantadine or a neuraminidase inhibitor (GG167) were additive with respect to anti-FluV activity, and the effect of the combination of ribavirin and 2Ј-fluoro-2Ј-deoxyguanosine was reported to be synergistic (12) . The combination of ribavirin and S-adenosylhomocysteine hydrolase inhibitors showed a synergistic antivaccinia virus effect (11) .
The mechanisms of the antiviral activities of PM-523 and FIG. 3 . Therapeutic effects of aerosol treatment of FluV A-infected mice with PM-523 and ribavirin. Mice were inoculated with virus (1.6 ϫ 10 4 TCID 50 s) intranasally, and the mice were exposed to solutions of the compounds at the indicated concentrations for 2 h. The mice were exposed to the compounds every 12 h for 4 days starting at 8 h after virus inoculation. F, untreated control; --, ribavirin at 40 mM; s, ribavirin at 80 mM; ϫ, ribavirin at 240 mM; Ç, PM-523 at 2.4 mM; ᮀ, PM-523 at 4.8 mM; å, PM-523 at 1.2 mM plus ribavirin at 20 mM; E, PM-523 at 2.4 mM plus ribavirin at 40 mM; ‫ء‬ and ", levels of significance of P Ͻ 0.001 and 0.001 Ͻ P Ͻ 0.005 against controls, respectively; #, a level of significance of P Ͻ 0.001 against 40 mM ribavirin and 2.4 mM PM-523, P Ͻ 0.01 against 4.8 mM PM-523, and P Ͻ 0.05 against 80 mM ribavirin. ribavirin seem to be quite different and nonexclusive. The former inhibits fusion of the FluV envelope and the cell membrane, while the latter mainly inhibits nucleoside metabolism and mediates a decrease in the size of the GMP pool in cells. However, some polyoxotungstates which contain silicon or antimony are known to inhibit the reverse transcriptase of human immunodeficiency virus type 1 (13) and the RNA-dependent RNA polymerase of flaviviruses, while they are less inhibitory to DNA-dependent DNA polymerases (3). A polyoxotungstate with Keggin sandwich structure (HS-12) was shown to penetrate cell membranes and locate close to the nucleus (5). On the basis of the information presented in those reports, it is possible that PM-523 also inhibits FluV RNA polymerase activity inside cells. For the in vivo experiments with combination therapy for infected mice, we used a 1:16 ratio of PM-523 to ribavirin since this ratio resulted in a synergistic inhibitory effect in the in vitro experiment. As indicated in Fig. 3 , a combination of 2.4 mM PM-523 (0.5 the EC 50 ) and 40 mM ribavirin (0.57 the EC 50 ) protected 80% of the infected mice from death on the 9th day following infection, while 90 to 100% of infected mice died, despite a single treatment with the same dose of each compound (Fig. 3) . The virus titers in the lungs of infected mice were lowest for mice treated with a combination of the two compounds. The combination of PM-523 and ribavirin apparently inhibited virus replication in the lungs of the infected mice and exhibited a better therapeutic effect on lethal FluV infection in mice than monotherapy with each compound. It is noteworthy that the duration of exposure of the compounds to the mice was only 4 h (2 ϫ 2 h) per day. This is a much shorter duration of exposure than those used in the previous studies of aerosol treatment of FluV-infected mice or patients reported by other workers (19, 20) . It is rather difficult to elucidate the mechanism of the therapeutic effect of the combination of the two compounds in an in vivo infection. Activation of the phagocytic activity of peritoneal macrophages by a polyoxotungstate (PM-19) was previously reported (10) , and if PM-523 has the same effect on alveolar macrophages, this may also enhance the therapeutic action of PM-523 in FluV-infected mice.
In conclusion, the combination of PM-523 and ribavirin synergistically inhibited in vitro virus replication. Aerosol treatment with each compound individually appeared to be well tolerated by the mice and was effective against FluV infection in mice. In addition, a combination of both compounds exhibited significantly increased therapeutic potency. It would therefore seem to be worth investigating PM-523 and ribavirin in combination for the clinical treatment of FluV infection.
